Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iGlarLixi vs Insulin Glargine and Lixisenatide in T2DM (LixiLan-O-AP)
NCT03798054Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2019
- Primary completion
- Mar 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoint: Change in Glycated Hemoglobin A1c at 24 weeks. Started Feb 2019; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03798054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798054.